Literature DB >> 7419475

Effect of bestatin on mouse immune system and experimental murine tumors.

M Ishizuka, T Masuda, N Kanbayashi, S Fukasawa, T Takeuchi, T Aoyagi, H Umezawa.   

Abstract

Effect of bestatin on the establishment of delayed-type hypersensitivity (DTH) to sheep red blood cells (SRBC) and oxazolone was examined in normal and immunity-impaired mice. Administration of a low dose of bestatin (0.1 approximately 100 microgram/mouse) augmented DTH to SRBC and restored their impaired DTH to oxazolone. The effect of bestatin in the mouse was age-dependent. Bestatin retarded the growth of slow growing solid tumors of Gardner lymphosarcoma and IMC carcinoma and the effect was influenced by the time of the administration and the number of cells inoculated. Bestatin enhanced the antitumor action of the antitumor antibiotics, bleomycin and adriamycin. Bestatin also retarded the induction of skin cancer by 20-methylcholanthrene.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7419475     DOI: 10.7164/antibiotics.33.642

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  10 in total

1.  Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases.

Authors:  F Abe; G Alvord; M Koyama; A Matsuda; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults.

Authors:  K Ota; S Kurita; K Yamada; T Masaoka; Y Uzuka; N Ogawa
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial.

Authors:  H Blomgren; I Näslund; P L Esposti; L Johansen; O Aaskoven
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice.

Authors:  F Abe; A Matsuda; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin).

Authors:  J Yoneda; I Saiki; H Fujii; F Abe; Y Kojima; I Azuma
Journal:  Clin Exp Metastasis       Date:  1992-01       Impact factor: 5.150

6.  Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice.

Authors:  F Abe; M Schneider; P L Black; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG.

Authors:  T Kataoka; S Yamamoto; T Yamamoto; E Kuramoto; Y Kimura; O Yano; T Tokunaga
Journal:  Jpn J Cancer Res       Date:  1992-03

8.  Antimetastatic effect of a novel indolocarbazole (NB-506) on IMC-HM murine tumor cells metastasized to the liver.

Authors:  H Arakawa; H Matsumoto; M Morita; M Sasaki; K Taguchi; A Okura; S Nishimura
Journal:  Jpn J Cancer Res       Date:  1996-05

9.  Inhibition of tumor cell invasion by ubenimex (bestatin) in vitro.

Authors:  I Saiki; J Murata; K Watanabe; H Fujii; F Abe; I Azuma
Journal:  Jpn J Cancer Res       Date:  1989-09

10.  Inhibition of aminopeptidases N, A and W. A re-evaluation of the actions of bestatin and inhibitors of angiotensin converting enzyme.

Authors:  S Tieku; N M Hooper
Journal:  Biochem Pharmacol       Date:  1992-11-03       Impact factor: 5.858

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.